Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 09:18 am Sale | 2024-12-31 | 13G | VTEX VTEX | Polar Capital Holdings Plc | 5,232,020 2.840% | -5,306,653 (-50.35%) | Filing History |
| 2025-02-14 09:17 am Sale | 2024-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | Polar Capital Holdings Plc | 2,389,668 4.890% | -298,129 (-11.09%) | Filing History |
| 2024-11-13 6:01 pm Purchase | 2024-09-30 | 13G | Bruker Corporation BRKR | Polar Capital Holdings Plc | 317,928 0.210% | 317,928 (New Position) | Filing History |
| 2024-11-13 6:00 pm Sale | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Polar Capital Holdings Plc | 2,711,163 4.090% | -424,708 (-13.54%) | Filing History |
| 2024-11-13 5:58 pm Sale | 2024-09-30 | 13G | Avadel Pharmaceuticals plc AVDL | Polar Capital Holdings Plc | 4,803,899 4.990% | -1,947,883 (-28.85%) | Filing History |
| 2024-11-13 5:57 pm Purchase | 2024-09-30 | 13G | VTEX VTEX | Polar Capital Holdings Plc | 10,538,673 5.700% | 10,538,673 (New Position) | Filing History |
| 2024-11-13 5:56 pm Purchase | 2024-09-30 | 13G | Hagerty, Inc. HGTY | Polar Capital Holdings Plc | 5,002,477 5.570% | 5,002,477 (New Position) | Filing History |
| 2024-11-13 5:55 pm Purchase | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | Polar Capital Holdings Plc | 2,687,797 5.690% | 2,687,797 (New Position) | Filing History |
| 2024-02-13 09:41 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Polar Capital Holdings Plc | 3,135,871 5.730% | 3,135,871 (New Position) | Filing History |
| 2024-02-13 09:40 am Purchase | 2023-12-31 | 13G | Avadel Pharmaceuticals plc AVDL | Polar Capital Holdings Plc | 6,751,782 7.510% | 3,957,109 (+141.59%) | Filing History |
| 2024-02-13 09:39 am Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Polar Capital Holdings Plc | 500,000 1.050% | 500,000 (New Position) | Filing History |
| 2024-02-13 09:39 am Sale | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Polar Capital Holdings Plc | 3,169,239 3.600% | -1,679,394 (-34.64%) | Filing History |
| 2024-02-13 09:27 am Purchase | 2023-12-31 | 13G | NanoString Technologies, Inc. NSTGQ | Polar Capital Holdings Plc | 3,975,000 8.260% | 196,269 (+5.19%) | Filing History |
| 2024-02-13 09:26 am Sale | 2023-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Polar Capital Holdings Plc | 6,297,688 6.670% | -820,256 (-11.52%) | Filing History |
| 2023-11-16 1:13 pm Purchase | 2023-10-20 | 13G | Arcutis Biotherapeutics, Inc. ARQT | Polar Capital Holdings Plc | 7,117,944 7.560% | 7,117,944 (New Position) | Filing History |
| 2023-07-28 09:01 am Purchase | 2023-07-19 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Polar Capital Holdings Plc | 157,448 5.020% | 157,448 (New Position) | Filing History |
| 2023-07-13 1:43 pm Unchanged | 2022-12-31 | 13G | NanoString Technologies, Inc. NSTGQ | Polar Capital Holdings Plc | 3,778,731 8.100% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:03 pm Sale | 2022-12-31 | 13G | Summit Therapeutics Inc. SMMT | Polar Capital Holdings Plc | 0 0.000% | -6,295,713 (Position Closed) | Filing History |
| 2023-02-14 4:02 pm Purchase | 2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC | Polar Capital Holdings Plc | 4,848,633 5.900% | 4,848,633 (New Position) | Filing History |
| 2023-02-14 4:01 pm Sale | 2022-12-31 | 13G | Quotient Limited QTNT | Polar Capital Holdings Plc | 0 0.000% | -231,291 (Position Closed) | Filing History |